Specify a stock or a cryptocurrency in the search bar to get a summary
Immix Biopharma Inc
IMMXImmix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California. Address: 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
Analytics
WallStreet Target Price
7 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures IMMX
Dividend Analytics IMMX
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History IMMX
Stock Valuation IMMX
Financials IMMX
Results | 2019 | Dynamics |